BIOA Stock Summary and Trading Ideas (Bioage Labs | NASDAQ:BIOA)

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Bioage Labs trades on the NASDAQ stock market under the symbol BIOA.

As of March 27, 2026, BIOA stock price declined to $16.15 with 278,278 million shares trading.

BIOA has a beta of 1.57, meaning it tends to be more sensitive to market movements. BIOA has a correlation of 0.13 to the broad based SPY ETF.

BIOA has a market cap of $716.73 million. This is considered a Small Cap stock.

Last quarter Bioage Labs reported $3 million in Revenue and -$.72 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.01.

The top ETF exchange traded funds that BIOA belongs to (by Net Assets): VTI, IWM, VXF, IWN, XPH.

BIOA has outperformed the market in the last year with a return of +316.2%, while the SPY ETF gained +13.1%. In the last 3 month period, BIOA beat the market returning +16.4%, while SPY returned -7.9%. However, in the most recent 2 weeks BIOA has underperformed the stock market by returning -13.7%, while SPY returned -4.0%.

BIOA support price is $15.27 and resistance is $17.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIOA shares will trade within this expected range on the day.